Curative Biosciences

Curative Biosciences EBIT

The EBIT of Curative Biosciences (CBDX) as of Nov 20, 2026 is -53,200.00 USD. In the previous year, EBIT was -1.64 M USD — a change of -96.76% (higher).

EBIT

-53,200.00USD

YoY

-96.76%

Last updated:

In 2017, Curative Biosciences's EBIT was -53,200.00 USD, a -96.76% increase from the -1.64 M USD EBIT recorded in the previous year.

The Curative Biosciences EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2010
-60,000.00 USD
Jan 1, 2011
-2.88 M USD
Jan 1, 2012
-6.28 M USD
Jan 1, 2013
-838,300.00 USD
Jan 1, 2014
-468,658.00 USD
Jan 1, 2015
-1.71 M USD
Jan 1, 2016
-1.64 M USD
Jan 1, 2017
-53,200.00 USD
The Curative Biosciences EBIT history
YEAREBITYoY
-53,200.00USD-96.76%
-1.64 MUSD-3.78%
-1.71 MUSD+263.94%
-468,658.00USD-44.09%
-838,300.00USD-86.65%
-6.28 MUSD+118.03%
-2.88 MUSD+4,700.00%
-60,000.00USD+500.00%
-10,000.00USD-85.71%
-70,000.00USD+40.00%
-50,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curative Biosciences Revenue

Curative Biosciences Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2010
490,000.00 USD
-60,000.00 USD
-60,000.00 USD
Jan 1, 2011
170,000.00 USD
-2.88 M USD
-2.88 M USD
Jan 1, 2012
315,000.00 USD
-6.28 M USD
-8.00 M USD
Jan 1, 2013
162,000.00 USD
-838,300.00 USD
-6.64 M USD
Jan 1, 2014
0.00 USD
-468,658.00 USD
-30.00 M USD
Jan 1, 2015
0.00 USD
-1.71 M USD
-3.37 M USD
Jan 1, 2016
0.00 USD
-1.64 M USD
-1.66 M USD
Jan 1, 2017
0.00 USD
-53,200.00 USD
-53,195.00 USD

Curative Biosciences Margins

Curative Biosciences stock margins

The Curative Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Curative Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Curative Biosciences.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2010
4.08 %
-12.24 %
-12.24 %
Jan 1, 2011
64.71 %
-1,694.12 %
-1,694.12 %
Jan 1, 2012
42.48 %
-1,993.40 %
-2,539.11 %
Jan 1, 2013
34.75 %
-517.47 %
-4,097.41 %
Jan 1, 2014
34.75 %
- %
- %
Jan 1, 2015
34.75 %
- %
- %
Jan 1, 2016
34.75 %
- %
- %
Jan 1, 2017
34.75 %
- %
- %

Curative Biosciences Stock analysis

What does Curative Biosciences do? Curative Biosciences Inc is a biotechnology company specializing in the development of innovative therapies for serious diseases. The company was founded in 2011 by a group of experienced scientists, medical experts, and entrepreneurs and is based in San Francisco, California. History Curative Biosciences Inc aims to develop groundbreaking therapies for diseases that currently have no effective treatment options. The company has had an impressive track record in recent years, as evidenced by numerous awards and recognition from reputable institutions and media. Business Model Curative Biosciences Inc has developed a unique business model based on the combination of basic research, product development, and marketing. The company conducts intensive research to identify and develop promising drug candidates. Divisions Curative Biosciences Inc has focused on several divisions to offer a wide range of innovative therapy options: - Oncology: Curative Biosciences Inc has developed a portfolio of drug candidates that specifically target malignant tumors without damaging healthy tissue. - Autoimmune diseases: The company has also developed some promising drug candidates for autoimmune diseases that regulate the immune system and reduce the risk of side effects and complications. - Neurodegenerative diseases: Curative Biosciences Inc is intensively working on the development of therapies against neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Products The company has already developed several promising products that are currently in clinical trials. Here are some examples: - CB-01: A drug candidate specifically developed to target aggressive tumors such as lung cancer, pancreatic cancer, and leukemia. - CB-02: A drug candidate that regulates the immune system and could be used in the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. - CB-03: A promising drug candidate against Alzheimer's disease that reduces β-amyloid proteins in the brain and could slow down the progression of the disease. Summary Curative Biosciences Inc is an emerging biotechnology company specializing in the development of innovative therapies for serious diseases. The company conducts intensive research and has already developed several promising drug candidates that are currently in clinical trials. Curative Biosciences Inc has developed a unique business model based on the combination of basic research, product development, and marketing. Curative Biosciences is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Curative Biosciences's EBIT

Curative Biosciences's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Curative Biosciences's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Curative Biosciences's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Curative Biosciences’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Curative Biosciences stock

EBIT of Curative Biosciences is -53,200.00 USD in 2017.

EBIT of Curative Biosciences changed from -1.64 M USD to -53,200.00 USD, representing a -96.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Curative Biosciences since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Curative Biosciences historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Curative Biosciences

All Key Metrics — Curative Biosciences